PCP2 and breast cancer: For example, “prolactin/ERK (extracellular signal-regulated kinase) signaling in breast cancer” was ranked ninth among GPSM1 statistically significant pathway analysis, and “mitogenic action of ESR1 (Estrogen Receptor 1) (membrane) in breast cancer” was ranked 15th for GPSM4.